|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_899631, 34452713|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||152786 Da|
|Application Notes||CAPS1 antibody can be used for detection of CAPS1 by Western blot at 0.25 - 0.5 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Target/Specificity||CADPS; Numerous isoforms of CAPS1 are known to exist. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.|
|Reconstitution & Storage||CAPS1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||CAPS1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||CAPS, CAPS1, KIAA1121|
|Function||Calcium-binding protein involved in exocytosis of vesicles filled with neurotransmitters and neuropeptides. Probably acts upstream of fusion in the biogenesis or maintenance of mature secretory vesicles. Regulates catecholamine loading of DCVs. May specifically mediate the Ca(2+)-dependent exocytosis of large dense-core vesicles (DCVs) and other dense-core vesicles by acting as a PtdIns(4,5)P2-binding protein that acts at prefusion step following ATP-dependent priming and participates in DCVs-membrane fusion. However, it may also participate in small clear synaptic vesicles (SVs) exocytosis and it is unclear whether its function is related to Ca(2+) triggering (By similarity).|
|Cellular Location||Cytoplasmic vesicle membrane; Peripheral membrane protein; Cytoplasmic side. Cell junction, synapse Note=Membrane-associated to vesicles. Strongly enriched in synaptic fractions. Preferentially binds to DCVs but not to SVs Binds phosphoinosides, with a strong selectivity for PtdIns(4,5)P2 over PtdIns(3,4,5)P3. Probably localizes to different vesicles compared to CADPS2 (By similarity).|
|Tissue Location||Specifically expressed in neural and endocrine secretory tissues. Expressed in brain and pancreas and at low level in heart. Also expressed in fetal heart, cerebellum, cerebral cortex, medulla, occipital pole, frontal and temporal lobes, and putamen, as well as weak expression in spinal cord|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CAPS1 Antibody: CAPS1 and its related protein CAPS2 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles; CAPS-deficienct neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. CAPS1 acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4, 5-bisphosphate and is thought to be a specific regulator of large dense-core vesicle fusion.
Walent JH, Porter BW, and Martin TF. A novel 145 kD brain cytosolic protein reconstitutes Ca(2+)-regulated secretion in permeable neuroendocrine cells. Cell1992; 70:765-775.
Juckusch WJ, Speidel D, Sigler A, et al. CAPS-1 and CAPS-2 are essential synaptic vesicle priming proteins. Cell2007; 131:796-808.
Rupnick M, Kreft M, Sikdat SK, et al. Rapid regulated dense-core vesicle exocytosis requires the CAPS protein. Proc. Natl. Acad. Sci. USA2000; 97:5627-32.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.